Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02664181
Title Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Decitabine + Nivolumab + Tetrahydrouridine

Age Groups: adult
Covered Countries USA


No variant requirements are available.